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Schizophrenia is a severe neuropsychiatric disorder that affects
around 0.5–1% of the population. Research has shown that early
intervention increases the likelihood of remission and reduces the
severity of symptoms, as well as attenuates the decline in social
and overall functioning.1
Around 30% of patients fail to respond adequately to the usual
antipsychotic medications, and are classified as being treatment
resistant. These patients can be treated with the atypical anti-
psychotic clozapine,2 the only evidence-based pharmacotherapy for
treatment-resistant schizophrenia.3 However, clozapine is associated
with severe adverse events and is thus only prescribed in patients
who have failed to respond to trials of two other antipsychotics.4
This process may take many years.5 Since an extended duration of
untreated psychosis and lack of efficacy for the initial treatment are
however associated with a poorer prognosis,6 identification of
patients who will eventually require clozapine is an important goal
for improving clinical outcome. Research to identify clinical
predictors of response prior to treatment initiation has shown that
premorbid social functioning (PSF) is among the most reliable
measures (for a review see Schennach et al.6). Furthermore, reports
of an association between a family history of psychosis and an
unfavourable treatment response7 suggest the influence of genetic
factors. However, few candidate gene studies have been conducted
and their results are inconsistent.8
The present study investigated whether a higher genetic risk for
schizophrenia is associated with treatment outcome. Genetic risk
was assessed by measuring the polygenic risk score, based on the
aggregated number of risk loci previously identified from
genome-wide association studies in schizophrenia patients9 with
a history of clozapine treatment (Cloz+, n= 434) compared to
patients with no history of clozapine treatment (Cloz−, n= 370).
Furthermore, the Cloz+ and Cloz− groups were compared in terms
of selected premorbid clinical features (that is, age and mode of
onset; poor premorbid work and social adjustment; premorbid
personality disorder; alcohol and drug abuse; family history of
schizophrenia and other psychiatric disorder; psychosocial stres-
sors; see Supplementary Information).
The polygenic risk score was increased in Cloz+ compared to
Cloz− patients (P= 0.02). Furthermore, polygenic risk scores were
higher in Cloz+ responders compared to Cloz+ non-responders
(P= 0.06).
Poor PSF was significantly more frequent in Cloz+ patients
(P= 8.1 × 10− 5; odds ratio (OR) = 1.85; confidence interval
(CI) = [1.35–2.55]). Cloz+ patients also displayed a significantly
earlier age-at-onset (x = 23.0; s.d. = 8.26) than Cloz− patients
(x = 25.5, s.d. = 9.12; P= 3.0 × 10− 6), and a higher frequency of
insidious disease onset (P= 4.4 × 10− 3). A correlation was
observed between poor PSF, early age-at-onset and insidious
disease onset. However, this was modest and did not exceed 23%
(for details see Supplementary Information). The highest polygenic
risk scores were observed in Cloz+ non-responders with poor PSF
and an insidious and early disease onset (P= 0.04; see Figure 1).
These clinical variables correlated with both treatment resistance
and polygenic score, and when included in the regression model
they diminished the influence of polygenic score to non-
significant values, whereas the associations with TRS per se, as
corrected for polygenic score, remained significant.
The finding that poor PSF, an insidious disease onset and an
early age-at-onset were associated with poor treatment response
is consistent with previous data.10 However, the present study is
the first to provide molecular evidence that an increased genetic
loading for schizophrenia is a further risk factor. However, full
interpretation of the results may depend on the proportion of
treatment-resistant individuals in the discovery sample (for further
discussion see Supplementary Information).
The absence of a positive family history of schizophrenia from
the list of associated outcome features may have been
attributable to the limited sample size. However, a post hoc
analysis showed that a positive family history of schizophrenia was
significantly associated with increased schizophrenia risk score in
the overall sample (see Supplementary Table 4).
Our findings may suggest the existence of a more severe,
genetically based schizophrenia subgroup, for whom early
intervention with clozapine could be considered. This may have
important implications for clinical practice, and further research is
therefore warranted.
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Figure 1. Comparison of polygenetic risk scores between:
(A) population-based controls vs all schizophrenia patients (SCZ);
(B) patients responding to standard medication vs patients with
treatment-resistant schizophrenia (TRS) requiring clozapine treat-
ment; (C) patients responding to clozapine vs patients with extreme
treatment-resistant schizophrenia (ETRS) not even responding to
clozapine; (D) patients with ETRS only vs patients with ETRS and
additional poor premorbid social adjustment and early and insidious
disease onset (ETRS+; P-values derived from right-tailed logistic
regression models).
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